A single-pill treatment to suppress HIV proved as effective as existing therapies of up to 11 tablets daily, the latest advance in a scientific “golden age” for treating the virus even as rich ...

A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), may be able to effectively replace more complicated HIV treatment regimens used by ...

A phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral tablet that combines two current HIV treatment medications – bictegravir and ...

At 48 weeks, 1% of participants in both groups had an HIV-1 RNA level of 50 copies per milliliter or higher, meeting the ...

A new study has overcome a long-standing challenge: how to isolate and study elusive HIV-infected cells called authentic reservoir clones (ARCs) that evade the immune system, making the disease ...

The tiny shell protecting the HIV virus resembles a slightly rounded ice cream cone, but there is nothing sweet about it.

Real-world data show an ibalizumab-based regimen provides sustained virologic suppression in heavily treatment-experienced ...

Social and economic factors may drive COVID-19 hospitalization risk more than HIV status among reproductive-age women in the Southern US.

Steatotic liver disease is an increasingly recognised comorbidity linked to HIV treatment.

According to IDPH, Black people in Illinois continue to have the highest rates of new HIV cases, despite representing only 14% of the population, and organizations led by Black people are lobbying ...

Melissa Schnure, PhD, wants to make sure some of the country’s most vulnerable patients are protected — low-income people living with HIV who depend on federally funded HIV services.It is why Schnure, ...